Who are Saw Palmetto - first 24 weeks's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): tamsulosin and/or dutasteride, Saw Palmetto - weeks 24 - 48, Zeller Entspannung film coated tablet, Passiflora, Crataegus e Salix, Cimicifuga + Hiperico, Saw Palmetto - weeks 48 - 72.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/saw-palmetto-first-24-weeks.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Saw Palmetto - first 24 weeks — Competitive Intelligence Brief

Saw Palmetto - first 24 weeks (Saw Palmetto - first 24 weeks) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Phytotherapeutic. Area: Urology.

phase 3 Phytotherapeutic 5-alpha-reductase Urology Small molecule Live · refreshed every 30 min

Target snapshot

Saw Palmetto - first 24 weeks (Saw Palmetto - first 24 weeks) — University of Alabama at Birmingham. Saw palmetto may inhibit the conversion of testosterone to dihydrotestosterone (DHT), a hormone involved in hair loss and prostate issues.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Saw Palmetto - first 24 weeks TARGET	Saw Palmetto - first 24 weeks	University of Alabama at Birmingham	phase 3	Phytotherapeutic	5-alpha-reductase
tamsulosin and/or dutasteride	tamsulosin and/or dutasteride	Case Comprehensive Cancer Center	phase 3	Alpha-1 adrenergic receptor antagonist and 5-alpha-reductase inhibitor	Alpha-1 adrenergic receptor and 5-alpha-reductase
Saw Palmetto - weeks 24 - 48	Saw Palmetto - weeks 24 - 48	University of Alabama at Birmingham	phase 3	Phytotherapeutic	5-alpha-reductase
Zeller Entspannung film coated tablet	Zeller Entspannung film coated tablet	Max Zeller Soehne AG	marketed	Herbal preparation / Phytotherapeutic agent
Passiflora, Crataegus e Salix	Passiflora, Crataegus e Salix	Ativus Farmaceutica Ltda	phase 3	Herbal combination / Phytotherapeutic
Cimicifuga + Hiperico	Cimicifuga + Hiperico	Phytopharm Consulting Brazil	phase 3	Herbal combination / phytotherapeutic agent
Saw Palmetto - weeks 48 - 72	Saw Palmetto - weeks 48 - 72	University of Alabama at Birmingham	phase 3	Phytotherapeutic

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Phytotherapeutic class)

University of Alabama at Birmingham · 3 drugs in this class
VSM Geneesmiddelen b.v. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Saw Palmetto - first 24 weeks — Competitive Intelligence Brief. https://druglandscape.com/ci/saw-palmetto-first-24-weeks. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab